NextCure’s (NXTC) “Buy” Rating Reaffirmed at Needham & Company LLC

NextCure (NASDAQ:NXTC)‘s stock had its “buy” rating reaffirmed by equities researchers at Needham & Company LLC in a research note issued on Friday, Benzinga reports. They currently have a $4.00 price objective on the stock. Needham & Company LLC’s price objective indicates a potential upside of 148.45% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of NextCure in a research report on Friday, May 31st.

NextCure Stock Down 0.6 %

Shares of NXTC stock opened at $1.61 on Friday. The firm has a market cap of $45.03 million, a price-to-earnings ratio of -0.71 and a beta of 0.68. The company’s 50 day moving average is $1.55 and its 200 day moving average is $1.57. NextCure has a 52-week low of $0.98 and a 52-week high of $2.57.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.16). Analysts anticipate that NextCure will post -1.71 EPS for the current fiscal year.

Institutional Investors Weigh In On NextCure

Institutional investors have recently added to or reduced their stakes in the business. Marquette Asset Management LLC acquired a new stake in NextCure in the fourth quarter worth about $66,000. Acuitas Investments LLC lifted its holdings in shares of NextCure by 30.0% during the fourth quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock worth $425,000 after purchasing an additional 85,982 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of NextCure during the first quarter worth about $952,000. Cable Car Capital LLC acquired a new stake in shares of NextCure during the fourth quarter worth about $702,000. Finally, Vanguard Group Inc. lifted its holdings in shares of NextCure by 9.3% during the first quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock worth $2,202,000 after purchasing an additional 83,700 shares during the period. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.